预约演示
更新于：2026-06-03
Clobazam
氯巴占
更新于：2026-06-03
概要
基本信息
药物类型 小分子化药 |
别名 1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine、7-Chloro-1-methyl-5-phenyl-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione、CLB + [18] |
作用方式 激动剂 |
作用机制 GABAA receptor激动剂(γ-氨基丁酸 A 受体激动剂) |
在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H13ClN2O2 |
InChIKeyCXOXHMZGEKVPMT-UHFFFAOYSA-N |
CAS号22316-47-8 |
关联
41
项与 氯巴占 相关的临床试验CTR20254346
氯巴占口服混悬液人体生物等效性试验（预试验）
IRCT20220211053992N49
In vivo fasted-state bioequivalence study of Clobazam 250 mg/ml suspension manufactured by Ashbal shimi Pharmaceutical Co. compared to innovator product
CTR20243975
Frisium和依诺思治疗Lennox-Gastaut综合征的多中心、随机、交叉、对照临床试验
100 项与 氯巴占 相关的临床结果
登录后查看更多信息
100 项与 氯巴占 相关的转化医学
登录后查看更多信息
100 项与 氯巴占 相关的专利（医药）
登录后查看更多信息
2,400
项与 氯巴占 相关的文献（医药）2026-08-01EPILEPSY & BEHAVIOR
Impact of antiseizure medications on thyroid function in persons with epilepsy
Article
作者: Menon, Ramshekhar N ; Radhakrishnan, Ashalatha ; Bhasi, Ankith ; Koshy, Kiren G ; Rohith, Maraludevanapura Govindaiah ; Ram, Nadarajan Aravind ; Manisha, K Y ; Bharanidharan, Gurumurthy
BACKGROUND:
Antiseizure medications (ASMs) are central to epilepsy management but may disrupt endocrine function, particularly thyroid homeostasis. Subclinical and central hypothyroidism are increasingly recognized among ASM users, yet routine thyroid monitoring remains uncommon.
OBJECTIVE:
To evaluate the prevalence and patterns of thyroid dysfunction in epilepsy patients on ASMs and compare the impact of older versus newer ASMs on thyroid function.
METHODS:
This cross-sectional study included 203 patients with epilepsy admitted to a tertiary epilepsy care centre in South India between July 2013 and March 2014. Patients with known thyroid disorders or other conditions affecting thyroid function were excluded. Thyroid function tests (TSH, fT3, fT4) were performed. Subclinical hypothyroidism was defined as elevated TSH with normal fT3/fT4; central hypothyroidism as low fT3/fT4 with normal or low TSH. ASMs were categorized into older and newer groups. Data were analysed using SPSS with appropriate parametric and non-parametric methods.
RESULTS:
Subclinical hypothyroidism was found in 11.3% of patients, more common in generalized epilepsy (56.5%) than focal epilepsy (43.5%) (p = 0.005). Valproate and clonazepam were most frequently associated. Among patients on monotherapy, none on newer ASMs had subclinical hypothyroidism, whereas 14.9% on older ASMs were affected (p = 0.35). Central hypothyroidism occurred in 10.3%, predominantly among users of zonisamide, phenobarbital, oxcarbazepine, and clobazam. Both older and newer ASM groups showed similar central hypothyroidism rates (9.6% versus 9.1%) CONCLUSION: Both older and newer ASMs exert clinically significant effects on thyroid homeostasis. Older ASMs were more often linked to subclinical hypothyroidism, while central hypothyroidism risk was comparable across ASM types. Annual thyroid screening is recommended to detect dysfunction early and prevent metabolic and cardiovascular complications.
2026-08-01EPILEPSY & BEHAVIOR
Caregiver perspectives on disease burden and treatment priorities in KCNT1-related disorders
Article
作者: Abuhl, Amanda ; Poliquin, Sarah ; Bearden, David ; Drislane, Sarah ; Esposito, Kaitlyn ; Wright, Megan ; Bryan, Brad A ; Faria, Victor ; Boyce, Danielle ; Rosenberg, Allison ; West, Justin ; Terry, Ian
BACKGROUND:
Pathogenic variants in KCNT1, encoding the sodium-activated potassium channel KNa1.1 (Slack), cause severe developmental and epileptic encephalopathies marked by early-onset, treatment-resistant seizures and profound neurodevelopmental impairment. While clinical and electrophysiological features are well described, systematic caregiver-reported data on treatment effectiveness and family impact are limited.
METHODS:
The KCNT1 Epilepsy Foundation established an international online caregiver-reported registry. Caregivers of individuals with a clinical and/or genetic diagnosis of a KCNT1-related disorder completed structured surveys between April 2023 and January 2024. Data included demographics, genetic variants, seizure characteristics, treatment history, sleep behaviors, quality of life, and family impact using validated and custom instruments.
RESULTS:
Data from 62 individuals across 13 countries were analyzed. Seizure onset was early (median: 1 month), with diagnosis occurring shortly thereafter (median: 4 months). Sixteen distinct KCNT1 missense variants were reported across the cohort. Caregivers reported a high treatment burden, with a median of 2.5 concurrent antiseizure therapies. The ketogenic diet, clobazam, phenobarbital, and levetiracetam, and vagus nerve stimulation were perceived as highly beneficial, while many conventional antiseizure medications showed limited benefit or worsening. Profound challenges were reported, particularly in cognitive and physical functioning, along with substantial emotional and practical family burden. Treatment priorities extended beyond seizure control to include communication, overall health, and quality of life, with notable gaps between priorities and perceived effectiveness.
CONCLUSIONS:
Caregiver-reported data demonstrate severe burden and substantial unmet needs in KCNT1-related disorders, highlighting the importance of patient- and family-centered outcome measures in care and therapeutic development.
2026-06-01BRAIN & DEVELOPMENT
Management of febrile seizures in Türkiye: A nationwide survey of pediatricians and pediatric neurologists
Article
作者: Coşkun, Ayşe Nur ; Akıncı Göktaş, Özben
OBJECTIVE:
To compare treatment preferences and decision-making patterns of pediatricians and pediatric neurologists in Türkiye regarding febrile seizure (FS) management.
METHODS:
This cross-sectional survey was conducted between June and December 2024 using an online questionnaire distributed nationwide to pediatricians and pediatric neurologists. The 34-item survey assessed demographics, clinical experience, FS encounter frequency, and management strategies for simple febrile seizures (SFS), complex febrile seizures (CFS), and febrile status epilepticus (FSE). Statistical analyses were performed using SPSS, with categorical variables compared using chi-square tests.
RESULTS:
A total of 184 physicians participated (97 pediatric neurologists, 87 pediatricians). Pediatric neurologists reported higher monthly FS encounter rates (p < 0.001). In SFS, both groups avoided continuous antiseizure medication (ASM) and preferred rescue therapy. In CFS, pediatric neurologists more often used intermittent prophylaxis, mainly oral diazepam or clobazam, whereas pediatricians more frequently initiated continuous therapy, most commonly levetiracetam (p < 0.05). For FSE, most participants initiated treatment after the first episode, with continuous levetiracetam as the preferred agent. Family history of afebrile seizures and seizure duration most strongly influenced treatment decisions. Over half of respondents reported difficulty explaining intermittent prophylaxis to caregivers and suggested educational materials as helpful.
CONCLUSION:
FS management differs between pediatricians and pediatric neurologists in Türkiye, particularly for complex cases. Pediatric neurologists favor guideline-consistent intermittent benzodiazepine-based strategies, whereas pediatricians more often prescribe continuous ASMs. Clearer guidance and improved caregiver education are needed to support evidence-based practice.
100 项与 氯巴占 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| Lennox-Gastaut综合征 | 美国 | 2011-10-21 | |
| 癫痫发作 | 日本 | 2000-03-10 | |
| 焦虑症 | 澳大利亚 | 1991-08-01 | |
| 癫痫 | 澳大利亚 | 1991-08-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Dravet综合征 | 临床3期 | 美国 | 2015-03-01 | |
| Dravet综合征 | 临床3期 | 墨西哥 | 2015-03-01 | |
| 部分性癫痫持续状态 | 临床3期 | 美国 | 2014-07-01 | |
| 全身性癫痫 | 临床3期 | 美国 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 澳大利亚 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 白俄罗斯 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 印度 | 2007-08-01 | |
| 全身性癫痫 | 临床3期 | 立陶宛 | 2007-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Company_Website 人工标引  | N/A | - | (Epilepsy) | 鑰積觸艱餘襯鏇選醖鑰(憲選構襯鑰選衊獵壓憲) = more often switched from clobazam tablets or suspension, and had higher cannabidiol use than those in the epilepsy group. 蓋壓淵壓鬱糧廠鑰獵醖 (衊蓋鏇遞遞願顧膚顧襯 ) | 积极 | 2025-09-15 | |
(Lennox-Gastaut Syndrome) | |||||||
N/A | 癫痫 追加 | 48 | 艱鬱淵壓廠繭遞衊願餘(繭簾獵襯製築鏇醖膚範) = 鏇鹽醖鬱顧窪衊憲遞蓋 餘網壓簾繭獵選鏇願鬱 (蓋膚鹹積艱構鹹簾齋餘 ) 更多 | 积极 | 2025-05-30 | ||
N/A | 1,435 | 獵廠鬱艱繭糧艱築壓網(窪憲簾衊鏇鏇選範窪鑰) = 鹽顧獵顧遞淵壓製窪齋 鏇遞構餘築鹹齋顧選鏇 (憲遞憲簾顧繭膚蓋夢築, 48 ~ 78) | 积极 | 2022-11-14 | |||
Other ASM Triple Therapy | 獵廠鬱艱繭糧艱築壓網(窪憲簾衊鏇鏇選範窪鑰) = 鬱蓋鬱選衊襯膚憲糧艱 鏇遞構餘築鹹齋顧選鏇 (憲遞憲簾顧繭膚蓋夢築, 47 ~ 75) | ||||||
N/A | 癫痫 追加 | 475 | 艱壓艱觸構壓鹹繭憲憲(鏇鏇鑰膚夢蓋觸鑰餘網) = 積願淵壓衊構遞獵壓築 齋遞積選觸鑰艱築艱範 (衊構鏇顧鬱襯艱窪網壓 ) | - | 2022-04-02 | ||
临床4期 | 20 | 廠襯觸襯夢簾憲淵簾窪(鹹鬱繭範構艱鹹積壓蓋) = 窪構壓艱膚壓襯鬱範製 淵糧網齋遞壓構鏇鬱窪 (築淵觸餘範遞鬱築齋窪, 簾鑰鏇繭遞觸餘範襯願 ~ 網選衊範壓願構膚範築) | - | 2021-03-04 | |||
N/A | 417 | 醖積衊遞選網積簾襯製(鹹積鏇選窪襯繭簾糧繭) = 醖鑰糧醖獵顧繭糧鏇鏇 憲顧鏇憲構顧範蓋獵壓 (築膚廠選製顧網繭餘糧 ) 更多 | 积极 | 2019-04-09 | |||
N/A | 196 | 繭廠觸糧艱憲網鹹衊鑰(夢衊齋憲築遞窪遞鬱糧) = 範廠夢壓齋淵膚淵獵鬱 構獵蓋願壓糧獵艱範範 (夢鏇選餘蓋選襯憲獵鹽 ) 更多 | 积极 | 2019-04-09 | |||
临床3期 | Dravet综合征 CYP3A4 | - | 餘膚膚製觸夢鬱繭願範(鹹願顧壓蓋衊壓窪願鹹) = 鹹壓獵鏇獵淵願鏇衊淵 遞壓鹽鹹襯積簾夢壓顧 (鏇餘願範網醖糧鹽糧襯 ) 更多 | - | 2018-04-10 | ||
餘膚膚製觸夢鬱繭願範(鹹願顧壓蓋衊壓窪願鹹) = 積鑰蓋網簾衊繭積襯淵 遞壓鹽鹹襯積簾夢壓顧 (鏇餘願範網醖糧鹽糧襯 ) 更多 | |||||||
临床3期 | 3 | 襯獵構膚艱繭獵選繭積 = 淵繭遞齋廠遞選鹽選選 獵鹽餘遞積鏇獵鹽願憲 (鏇構觸遞淵窪壓築繭衊, 蓋遞淵築膚鹽顧製淵醖 ~ 繭鏇壓夢繭範窪齋簾憲) 更多 | - | 2017-02-15 | |||
临床3期 | 206 | Clobazam high dosage | 壓獵膚鬱夢顧構製夢築(窪膚願積製艱廠餘積憲) = 夢願餘願餘範觸齋壓窪 選壓積膚壓鏇積網壓衊 (願顧淵鏇網簾顧窪積壓 ) | - | 2016-04-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用